CJC-1295 DAC + Ipamorelin 5+5 mg
Dual GH-secretagogue stack combining extended-release CJC-1295 DAC with pulsatile Ipamorelin for synergistic endocrine axis research.
Mechanism
CJC-1295 DAC prolongs pituitary GHRH receptor activation via albumin conjugation while Ipamorelin selectively triggers pulsatile growth hormone release through the GHS-R1a ghrelin receptor.
Dosing
Standard laboratory protocols document starting administrations of 0.5 to 1 mg weekly for CJC-1295 DAC alongside daily Ipamorelin evaluations of 300 to 500 mcg.
Reconstitution
Reconstitute each 5 mg vial independently with 2.5 mL of bacteriostatic water to obtain a standardized 2.0 mg/mL concentration per peptide.
Storage
Store lyophilized vials at 2–8°C away from light; once reconstituted, maintain refrigerated at 2–8°C and use within 14 to 28 days without freezing.
Mix & measure CJC-1295 DAC + Ipamorelin 5+5 mg
Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.
Mix & measure CJC-1295 DAC + Ipamorelin 5+5 mg
Vial strength → BAC water → target dose
Total doses in vial: 10.0
U-100 syringe: 100 units = 1 mL
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →
Dosing Chart
| Phase / Day(s) | Dose & Frequency | Volume (U-100 units / mL) |
|---|---|---|
| Weeks 1–4 (CJC-1295 DAC) | 0.5–1 mg (1–2× weekly) | 0.2–0.4 mL (20–40 units) |
| Weeks 1–4 (Ipamorelin) | 300–500 mcg (1× daily) | 0.18–0.3 mL (18–30 units) |
| Advanced Phase (CJC-1295 DAC) | ~1 mg (3× weekly, 3 mg total) | 0.2 mL (20 units) |
| Advanced Phase (Ipamorelin) | 300–350 mcg (2× daily) | 0.06–0.07 mL (6–7 units) |
Reconstitution Steps
- 1
Sanitize the rubber septums of both the peptide vials and the bacteriostatic water container with individual sterile alcohol prep pads.
- 2
Draw the designated volume of bacteriostatic water into a sterile mixing syringe.
- 3
Carefully introduce the diluent into the vial, directing the stream down the inside glass wall to prevent aerosolization or mechanical shear.
- 4
Swirl the vial gently with circular motions until the lyophilized pellet dissolves completely, avoiding vigorous agitation or shaking.
- 5
Place the reconstituted solution immediately into refrigeration at 2–8°C, shielding the peptide from direct illumination.
Supplies Needed
Peptide Vial
Provides 5 mg of lyophilized CJC-1295 DAC and 5 mg of lyophilized Ipamorelin in separate containers for experimental evaluation.
Insulin Syringes (U-100)
Facilitates accurate volumetric measurement and delivery of micro-volume doses for each compound independently.
Bacteriostatic Water
Serves as a sterile, preserved diluent to reconstitute the lyophilized peptide cakes into liquid solution.
Alcohol Swabs
Disinfects vial stoppers and preparation surfaces to maintain aseptic handling throughout the research procedure.
Why researchers study it
Investigation of basal and pulsatile GH/IGF-1 axis dynamics
Preclinical evaluation of lipolytic pathways and body composition changes
Connective tissue remodeling and musculoskeletal repair signaling
Analysis of somatotropic tone and slow-wave sleep architecture
These describe what is being studied, not proven benefits, approved uses, or promised results.
Overview
The CJC-1295 DAC and Ipamorelin stack provides a dual-pathway approach to exploring growth hormone axis dynamics in experimental models. CJC-1295 with Drug Affinity Complex (DAC) is a long-acting growth hormone-releasing hormone (GHRH) derivative engineered to covalently bind to endogenous albumin, producing persistent basal elevations of systemic growth hormone and downstream IGF-1. In contrast, Ipamorelin operates as a selective pentapeptide agonist of the growth hormone secretagogue receptor (GHS-R1a/ghrelin receptor), eliciting sharp, targeted secretory spikes. By integrating these two agents as an experimental stack, researchers investigate the potential synergy of concurrent basal stimulation and pulsatile release. Unlike non-selective secretagogues, Ipamorelin demonstrates minimal off-target provocation of adrenocorticotropic hormone (ACTH), cortisol, or prolactin, allowing investigators to observe isolated somatotropic effects without widespread neuroendocrine confounding. This protocol outlines individual reconstitution and handling considerations for both peptide vials. Because this pairing consists of two separate molecular entities intended for concurrent investigation rather than a pre-mixed compound, maintaining separate preparation pathways and calculating distinct volumetric withdrawals ensures controlled and reproducible laboratory evaluation.
References
- 1.Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006 — Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults
- 2.Raun et al., European Journal of Endocrinology, 1998 — Ipamorelin, the first selective growth hormone secretagogue, with minimal effect on cortisol and prolactin
- 3.Smith et al., Endocrine Reviews, 1997 — Growth hormone secretagogues: mechanisms of action and clinical applications
- 4.Steiger et al., Sleep Medicine Reviews, 2007 — Sleep and the GH/IGF-1 axis: physiological and clinical implications
Supplies Needed
Suggested supplier
Research use only. Listing a supplier is not an endorsement of any protocol on this site, and nothing sold there is approved for human use.